PMID- 19623601
OWN - NLM
STAT- MEDLINE
DCOM- 20110120
LR  - 20181201
IS  - 1099-1166 (Electronic)
IS  - 0885-6230 (Linking)
VI  - 25
IP  - 3
DP  - 2010 Mar
TI  - The long-term efficacy and tolerability of donepezil in patients with vascular 
      dementia.
PG  - 305-13
LID - 10.1002/gps.2340 [doi]
AB  - OBJECTIVE: To determine the long-term tolerability and efficacy of donepezil in 
      patients with vascular dementia (VaD). METHODS: International, multicentre, 
      open-label, 30-week extension study of two 24-week, randomised, double-blind, 
      placebo-controlled studies. Participants were ambulatory adults (59% female; mean 
      age, 74.7 +/- 0.3) with a diagnosis of possible or probable VaD and without a 
      diagnosis of Alzheimer's disease, who were medically stable and had completed one 
      of two double-blind studies. All patients received donepezil 5 mg/day for the 
      first 6 weeks, then 10 mg/day (clinician approval required). Assessments were 
      performed at week 6 and every 12 weeks thereafter. The main outcome measure was 
      the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-cog). 
      Safety/tolerability measures included adverse events (AEs) and physical and 
      laboratory evaluations. RESULTS: Of 1219 eligible patients, 885 (72.6%) were 
      enrolled, of which 707 (79.9%) completed the study; 127 (14.4%) patients 
      discontinued due to AEs. A mean reduction (0.6-1.15 points) from double-blind 
      study baseline score to week 54 (end of open-label study) on the ADAS-cog was 
      observed for patients who received donepezil continuously for 54 weeks. ADAS-cog 
      scores remained stable in the group that initiated donepezil treatment during the 
      extension study. Most common donepezil-related AEs were nausea (occurring in 
      5.3%) and diarrhoea (8.8%); no unexpected AEs attributable to donepezil occurred. 
      CONCLUSION: These data suggest that donepezil improves cognition for up to 54 
      weeks in patients with VaD. Patients initiating donepezil in this extension study 
      did not perform as well on the primary outcome measure as those initiating 
      donepezil in the double-blind study.
FAU - Wilkinson, David
AU  - Wilkinson D
AD  - Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK.
FAU - Roman, Gustavo
AU  - Roman G
FAU - Salloway, Stephen
AU  - Salloway S
FAU - Hecker, Jane
AU  - Hecker J
FAU - Boundy, Karyn
AU  - Boundy K
FAU - Kumar, Dinesh
AU  - Kumar D
FAU - Posner, Holly
AU  - Posner H
FAU - Schindler, Rachel
AU  - Schindler R
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int J Geriatr Psychiatry
JT  - International journal of geriatric psychiatry
JID - 8710629
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Indans)
RN  - 0 (Piperidines)
RN  - 8SSC91326P (Donepezil)
SB  - IM
MH  - Aged
MH  - Alzheimer Disease/drug therapy/psychology
MH  - Cholinesterase Inhibitors/adverse effects/*therapeutic use
MH  - Cognition/drug effects
MH  - Dementia, Vascular/diagnosis/*drug therapy
MH  - Donepezil
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Indans/adverse effects/*therapeutic use
MH  - Male
MH  - Neuropsychological Tests
MH  - Piperidines/adverse effects/*therapeutic use
MH  - Psychiatric Status Rating Scales
EDAT- 2009/07/23 09:00
MHDA- 2011/01/21 06:00
CRDT- 2009/07/23 09:00
PHST- 2009/07/23 09:00 [entrez]
PHST- 2009/07/23 09:00 [pubmed]
PHST- 2011/01/21 06:00 [medline]
AID - 10.1002/gps.2340 [doi]
PST - ppublish
SO  - Int J Geriatr Psychiatry. 2010 Mar;25(3):305-13. doi: 10.1002/gps.2340.